Evaluation of Liver Injury Mark J Czaja Liver

  • Slides: 59
Download presentation
Evaluation of Liver Injury Mark J. Czaja Liver Research Center Albert Einstein College of

Evaluation of Liver Injury Mark J. Czaja Liver Research Center Albert Einstein College of Medicine Bronx, N. Y.

Liver Function Tests • • • Alanine aminotransferase (ALT) Aspartate aminotransferase (AST) Lactate dehydrogenase

Liver Function Tests • • • Alanine aminotransferase (ALT) Aspartate aminotransferase (AST) Lactate dehydrogenase (LDH) Alkaline phosphatase Bilirubin Albumin

Mechanisms of Liver Dysfunction • Direct cellular injury • Blockage in bile flow •

Mechanisms of Liver Dysfunction • Direct cellular injury • Blockage in bile flow • Impaired blood flow

Direct Cellular Injury - HCV Infection

Direct Cellular Injury - HCV Infection

Blockage in Bile Flow - Biliary Atresia

Blockage in Bile Flow - Biliary Atresia

Impaired Blood Flow - CHF

Impaired Blood Flow - CHF

Consequences of Liver Injury liver cell injury liver cell death proliferation matrix deposition sufficient

Consequences of Liver Injury liver cell injury liver cell death proliferation matrix deposition sufficient inadequate altered architecture recovery liver failure cirrhosis

Types of Liver Tests • True tests of liver function • Biochemical markers of

Types of Liver Tests • True tests of liver function • Biochemical markers of liver injury • Biochemical markers of specific liver diseases

Testable Biochemical Liver Function • Ability to transport organic anions • Capacity to metabolize

Testable Biochemical Liver Function • Ability to transport organic anions • Capacity to metabolize certain substances • Capability to synthesize various proteins

Steps in Organic Anion Transport • Delivery and uptake • Metabolic alteration • Secretion

Steps in Organic Anion Transport • Delivery and uptake • Metabolic alteration • Secretion and excretion

Bilirubin • • • Tetrapyrole Toxic in neonates - kernicterus Derived from: Senescent RBC

Bilirubin • • • Tetrapyrole Toxic in neonates - kernicterus Derived from: Senescent RBC (70 -80%) l Hemoproteins (20 -30%) l Ineffective erythropoiesis l

Bilirubin Formation heme biliverdin heme oxygenasebiliverdin bilirubin reductase Transport: hydrophobic due to internal H-bonding

Bilirubin Formation heme biliverdin heme oxygenasebiliverdin bilirubin reductase Transport: hydrophobic due to internal H-bonding circulates bound to albumin

Bilirubin Metabolism Plasma Bile Hepatocyte Alb UCB BMG BDG UCB ligandin BMG transferase BDG

Bilirubin Metabolism Plasma Bile Hepatocyte Alb UCB BMG BDG UCB ligandin BMG transferase BDG glucuronyl

Bilirubin Elimination Intestine • BMG (20%) + BDG (80%) +UCB (trace) • Deconjugated to

Bilirubin Elimination Intestine • BMG (20%) + BDG (80%) +UCB (trace) • Deconjugated to urobilinogen • Excreted or reabsorbed (20%) Urine • BMG and BDG • No UCB

Measurement of Serum Bilirubin • • Normal concentration < 1 mg/dl Conjugated < 5%

Measurement of Serum Bilirubin • • Normal concentration < 1 mg/dl Conjugated < 5% Jaundice if > 3 mg/dl Detected by diazo reaction - cleaved to colored azo-dipyrole l l Conjugated reacts rapidly (direct) Unconjugated reacts slowly (indirect)

Differential Diagnosis I • Prehepatic • Intrahepatic Congenital l Acquired l • Posthepatic

Differential Diagnosis I • Prehepatic • Intrahepatic Congenital l Acquired l • Posthepatic

Differential Diagnosis II • Unconjugated hyperbilirubinemia l l l Increased bilirubin production (hematological) Decreased

Differential Diagnosis II • Unconjugated hyperbilirubinemia l l l Increased bilirubin production (hematological) Decreased uptake (drug) Decreased conjugation (congenital) • Conjugated hyperbilirubinemia l l Congenital Drug Liver disease Biliary obstruction

Inherited Disorders Causing Unconjugated Hyperbilirubinemia • Crigler-Najjar syndrome l Type 1 – absent GT

Inherited Disorders Causing Unconjugated Hyperbilirubinemia • Crigler-Najjar syndrome l Type 1 – absent GT l Type 2 – reduced GT activity • Gilbert’s syndrome – reduced GT activity due to genetic defect in TATAA element of GT promoter

Inherited Disorders Causing Conjugated Hyperbilirubinemia • Dubin-Johnson syndrome – mutations in multidrug resistance associated

Inherited Disorders Causing Conjugated Hyperbilirubinemia • Dubin-Johnson syndrome – mutations in multidrug resistance associated protein 2 (MRP 2) • Rotor’s syndrome – genetic defect

Hepatic Metabolic Capacity • Clearance must depend on total functional mass or metabolic activity

Hepatic Metabolic Capacity • Clearance must depend on total functional mass or metabolic activity • Hepatic drug metabolism [14 C]amino-pyrine breath test • Galactose elimination • Not used clinically

Hepatic Synthetic Capacity • Most major plasma proteins are made in the liver •

Hepatic Synthetic Capacity • Most major plasma proteins are made in the liver • Decreased hepatocytes = decreased protein synthesis and release • Albumin and coagulation factors are clinically important

Albumin • 50% of all synthesized hepatic protein • Determinant of plasma oncotic pressure

Albumin • 50% of all synthesized hepatic protein • Determinant of plasma oncotic pressure • Important transport protein

Serum Albumin Levels • Long half-life of 20 days • Large hepatic synthetic reserve

Serum Albumin Levels • Long half-life of 20 days • Large hepatic synthetic reserve • Decreased with persistent, large injury • Decreased in chronic liver disease • Poor prognostic sign

Non-hepatic Causes of Hypoalbuminemia • Severe malnutrition • Renal or GI loss l Glomerulopathy,

Non-hepatic Causes of Hypoalbuminemia • Severe malnutrition • Renal or GI loss l Glomerulopathy, HIV enteropathy • High catabolism l Infections, burns

Coagulation Factors • Half-lives of hours to days • Liver synthesizes I, II, V,

Coagulation Factors • Half-lives of hours to days • Liver synthesizes I, II, V, VII, IX, and X • Large synthetic reserve

Prothrombin Time (PT) • PT detects abnormalities in I, II, V, VII and X

Prothrombin Time (PT) • PT detects abnormalities in I, II, V, VII and X (extrinsic pathway) • PT is increased in liver disease • Best prognostic indicator l l Acute liver disease Chronic liver disease

Non-hepatic Causes of Elevated PT • Congenital coagulation factor deficiencies • Consumptive coagulopathies •

Non-hepatic Causes of Elevated PT • Congenital coagulation factor deficiencies • Consumptive coagulopathies • Vitamin K deficiency (II, VII, IX, X)

To Rule Out Vitamin K Deficiency • Any patient with an elevated PT •

To Rule Out Vitamin K Deficiency • Any patient with an elevated PT • Parental vitamin K for 3 days • Normalization of PT - vitamin K deficiency • Failure to normalize - hepatocellular disease

Serum Immunoglobulins • Not produced by hepatocytes • Frequently elevated in liver disease •

Serum Immunoglobulins • Not produced by hepatocytes • Frequently elevated in liver disease • Secondary to inflammatory process • ? produced by antigen shunting

Biochemical Markers of Liver Injury

Biochemical Markers of Liver Injury

Liver Enzymes • Low levels always present in serum • Leak out from cell

Liver Enzymes • Low levels always present in serum • Leak out from cell after injury • Very sensitive • Magnitude of abnormality does not correlate well with degree of injury

Aspartate Aminotransferase (AST) • Serum glutamic-oxaloacetic transaminase (SGOT) • Transfers an a-amino group of

Aspartate Aminotransferase (AST) • Serum glutamic-oxaloacetic transaminase (SGOT) • Transfers an a-amino group of aspartate to a-keto group of ketoglutaric acid • Present in skeletal muscle, kidney, brain

Alanine Aminotransferase (ALT) • Serum glutamic-pyruvic transaminase (SGPT) • Transfers an a-amino group of

Alanine Aminotransferase (ALT) • Serum glutamic-pyruvic transaminase (SGPT) • Transfers an a-amino group of alanine to a-keto group of ketoglutaric acid • Present principally in liver

AST and ALT • Elevated in most liver diseases • Highest levels are in

AST and ALT • Elevated in most liver diseases • Highest levels are in acute liver diseases • Only slight elevations in chronic liver diseases • Usually increase in parallel

AST/ALT in Alcoholic Hepatitis • Transaminases rarely exceed 300 • AST: ALT >2

AST/ALT in Alcoholic Hepatitis • Transaminases rarely exceed 300 • AST: ALT >2

Factors Affecting AST/ALT • Depressed by pyridoxine (vit. B 6) deficiency • Decreased by

Factors Affecting AST/ALT • Depressed by pyridoxine (vit. B 6) deficiency • Decreased by uremia and renal dialysis

AST/ALT Controversies • Should lower normal limits be used in females? l Females <

AST/ALT Controversies • Should lower normal limits be used in females? l Females < 30 vs. males < 40 • Are the normal limits too high? l Females < 20 and males < 30

Lactate Dehydrogenase (LDH) • Component of classic LFT’s • Highly non-specific

Lactate Dehydrogenase (LDH) • Component of classic LFT’s • Highly non-specific

Tests of Impaired Hepatic Excretion Increased In • Cholestasis • Intra-hepatic biliary tract obstruction

Tests of Impaired Hepatic Excretion Increased In • Cholestasis • Intra-hepatic biliary tract obstruction • Extra-hepatic biliary obstruction

Alkaline Phosphatase • Hydrolyzes phosphate esters at alkaline p. H • Also present in

Alkaline Phosphatase • Hydrolyzes phosphate esters at alkaline p. H • Also present in bone, kidney, placenta, intestine • Mainly liver and bone in adults • Increased in children from bone growth • Placental form during pregnancy

Elevated Alkaline Phosphatase • Can occur in any liver disease • Highest with cholestasis

Elevated Alkaline Phosphatase • Can occur in any liver disease • Highest with cholestasis or biliary tract obstruction • Elevated in infiltrative diseases • Due to increase synthesis and secretion

Alkaline Phosphatase Isoenzymes Source Heat Inactivation 5' NT GGTP Liver Moderate + + Bone

Alkaline Phosphatase Isoenzymes Source Heat Inactivation 5' NT GGTP Liver Moderate + + Bone Rapid - - Placenta Slow - - Intestine Slow - -

5'-Nucleotidase • Hydrolyzes 5'- adenosine monophosphate • Mainly present in liver • Increases along

5'-Nucleotidase • Hydrolyzes 5'- adenosine monophosphate • Mainly present in liver • Increases along with alkaline phosphatase

g-Glutamyl Transpeptidase (GGTP) • • Transfers g-glutamyl groups Widely distributed Sensitive correlate to alkaline

g-Glutamyl Transpeptidase (GGTP) • • Transfers g-glutamyl groups Widely distributed Sensitive correlate to alkaline phosphatase Non-specific (alcoholism, MI, DM, pancreatic disease, renal failure)

Biochemical Markers of Specific Liver Diseases

Biochemical Markers of Specific Liver Diseases

Etiology-specific Liver Tests • • • Viral hepatitis serologies Serum ferritin level Ceruloplasmin level

Etiology-specific Liver Tests • • • Viral hepatitis serologies Serum ferritin level Ceruloplasmin level Alpha 1 -antitrypsin level Antimitochondrial antibody titer

Viral Hepatitis Serology • HAV – anti-HAV Ig. M and Ig. G • HBV

Viral Hepatitis Serology • HAV – anti-HAV Ig. M and Ig. G • HBV – HBs. Ag, anti-HBs. Ag, and anti-HBc. Ag • HCV – anti-HCV, HCV RNA

Serum Ferritin • Widely distributed storage protein • Levels reflect body iron stores •

Serum Ferritin • Widely distributed storage protein • Levels reflect body iron stores • Elevated in primary hemochromatosis • Elevated in acute inflammation and cirrhosis

Serum Ceruloplasmin • • Copper-binding protein Decreased in 95% of patients with Wilson’s disease

Serum Ceruloplasmin • • Copper-binding protein Decreased in 95% of patients with Wilson’s disease • 20% of heterozygotes have decreased levels

a 1 -Antitrypsin • • Inhibits serum trypsin Major component of a 1 -globulin

a 1 -Antitrypsin • • Inhibits serum trypsin Major component of a 1 -globulin • Deficiency cause of neonatal hepatitis

Antimitochondrial Antibody (AMA) • Directed against mitochondrial enzyme pyruvate dehydrogenase complex • Positive in

Antimitochondrial Antibody (AMA) • Directed against mitochondrial enzyme pyruvate dehydrogenase complex • Positive in 90% of patients with primary biliary cirrhosis

Interpretation of Abnormal LFT’s • • • Examine multiple tests Consider non-hepatic causes Determine

Interpretation of Abnormal LFT’s • • • Examine multiple tests Consider non-hepatic causes Determine the most abnormal tests

Hepatocellular vs. Cholestatic Test Hepatocellular Cholestatic ALT/AST 2 -3 NL-1 Alk Phos NL-1 2

Hepatocellular vs. Cholestatic Test Hepatocellular Cholestatic ALT/AST 2 -3 NL-1 Alk Phos NL-1 2 -3 Bilirubin NL-3 Albumin NL-3 NL PT NL-3 NL

Case 1 25 yo IVDA c/o 1 week of nausea, vomiting, and myalgias. Physical

Case 1 25 yo IVDA c/o 1 week of nausea, vomiting, and myalgias. Physical exam revealed jaundice. • ALT 2045 (15 -45) • AST 2300 (15 -45) • Alk Phos 273 (50 -150) • Bili 3. 9 (0. 1 -1. 0) • Alb 4. 2 (3. 5 -5. 5) • PT 11. 5 (10 -12)

Hepatocellular W/U H&P Et. OH, medications, transfusions Risk for viral hepatitis Risk factors for

Hepatocellular W/U H&P Et. OH, medications, transfusions Risk for viral hepatitis Risk factors for NASH Etiology-specific LFT’s USG and liver biopsy Autoimmune features

HBV Infection - HBc. Ag Staining

HBV Infection - HBc. Ag Staining

Case 2 67 yo c/o several months of weight loss, and 1 week of

Case 2 67 yo c/o several months of weight loss, and 1 week of nausea, vomiting, and myalgias. Physical exam revealed cachexia and jaundice. • • • ALT 75 (15 -45) AST 115 (15 -45) Alk Phos 650 (50 -150) • • • Bili 10. 2 (0. 1 -1. 0) Alb 4. 2 (3. 5 -5. 5) PT 11. 0 (10 -12)

Cholestatic W/U H&P medications, gallstones, weight loss normal AMA liver biopsy USG dilated ducts

Cholestatic W/U H&P medications, gallstones, weight loss normal AMA liver biopsy USG dilated ducts ERCP

Pancreatic Carcinoma - ERCP

Pancreatic Carcinoma - ERCP